MK-2866 (Ostarine)

Quick Facts

Introduction

MK-2866 — widely known as Ostarine and developmentally as enobosarm — is a selective androgen-receptor modulator (SARM). Unlike the peptides that dominate this library, it is a small non-steroidal molecule, but it is frequently catalogued alongside them because it occupies the same research conversation around muscle and body-composition endpoints. It is studied for its ability to engage the androgen receptor (AR) in a tissue-selective way.

The central idea behind the SARM class is tissue selectivity: the aspiration is to produce the anabolic effects of androgen-receptor activation in muscle and bone while minimizing the activity in prostate, skin, and other androgenic tissues that characterizes traditional anabolic steroids. MK-2866 is one of the most extensively studied compounds built around this premise, and it is commonly examined alongside the more potent SARM RAD-140 and mechanistically distinct muscle-research compounds such as Follistatin-344 and MK-677.

This profile covers what MK-2866 is, its non-steroidal chemistry, its tissue-selective androgen-receptor mechanism, the lean-mass and bone research it appears in, and how it compares with related compounds. Related entries are catalogued in the peptide database.

What is MK-2866?

MK-2866 is a non-steroidal, orally active SARM originally developed within pharmaceutical research programs aimed at conditions involving muscle wasting. Chemically it is unrelated to testosterone and the steroidal anabolics: it lacks the steroid ring system entirely and instead is a synthetic aryl-propionamide-class small molecule designed to bind the androgen receptor with a distinctive activity profile.

That distinction matters because the steroid backbone of traditional anabolics is what makes them substrates for enzymes such as aromatase and 5α-reductase, generating estrogenic and other downstream metabolites. As a non-steroidal molecule, MK-2866 is studied as a compound that does not feed into those steroidal conversion pathways, which is part of the rationale researchers cite for its selectivity.

Because it is a small molecule rather than a peptide, MK-2866 is administered and handled very differently from the injectable peptides in this library — it is orally bioavailable and is typically worked with as a solution in an organic co-solvent rather than reconstituted in water.

Molecular and structural characteristics

MK-2866 is a small organic molecule of the aryl-propionamide chemical class, incorporating a trifluoromethyl and nitrile-substituted aromatic system. This non-steroidal scaffold is the structural feature that most clearly separates it from testosterone-derived anabolics and underlies its different metabolic and receptor-conformation behavior.

Unlike the folded proteins and linear peptides elsewhere in this library, MK-2866 has no disulfide bonds or tertiary structure to preserve. Its research-handling considerations therefore center on solubility and chemical stability rather than denaturation, since it is poorly water-soluble and is generally dissolved in a suitable organic co-solvent.

Mechanism of action

MK-2866 binds the androgen receptor, a ligand-activated nuclear transcription factor. When the compound binds, the receptor changes conformation, translocates to the nucleus, and regulates the transcription of androgen-responsive genes — the same fundamental mechanism through which testosterone acts, but reached via a different ligand chemistry.

The defining concept is tissue selectivity. The functional outcome of androgen-receptor activation depends on which co-regulatory proteins (coactivators and corepressors) are recruited in a given cell type, and that recruitment is shaped by the precise receptor conformation a ligand induces. SARMs like MK-2866 are studied because they are reported to favor conformations that drive anabolic gene programs in muscle and bone while producing comparatively weaker activation in tissues such as the prostate.

A second mechanistic point is the absence of steroidal metabolism. Because MK-2866 is not a steroid, it is not converted by aromatase to estrogens or by 5α-reductase to more potent androgens, a property researchers cite as part of its distinct profile relative to testosterone-based compounds. As with all androgen-receptor agonists, engagement of this central hormonal axis is studied to influence the body's own endocrine feedback.

• Binds the androgen receptor as a ligand-activated transcription factor.
• Induces receptor conformations favoring anabolic gene programs.
• Tissue-selective activity in muscle and bone vs androgenic tissues.
• Not a substrate for aromatase or 5α-reductase (non-steroidal).

Lean-mass and body-composition research

The leading research context for MK-2866 is lean body mass. Clinical research programs originally explored it in study populations affected by muscle-wasting conditions, where the goal was to preserve or increase lean mass. In those settings it has been associated with measurable gains in lean body mass and improvements in physical-function measures, observations that established it as a reference compound within the SARM class.

The mechanistic appeal in this research is the selectivity premise: achieving androgen-receptor-driven anabolic effects in muscle while limiting the androgenic activity that characterizes steroids. Researchers frame MK-2866 as a tool for testing how completely that separation can be achieved, rather than as an established therapy.

Within this library, MK-2866 sits alongside compounds that pursue muscle endpoints through entirely different routes — the myostatin antagonist Follistatin-344, the IGF-1 axis via MK-677, and the more potent SARM RAD-140 — which makes it a useful point of comparison across anabolic-research strategies.

Bone and physical-function research

Because androgen-receptor signaling supports bone maintenance, MK-2866 has also been studied for skeletal endpoints in preclinical models, where tissue-selective AR activation is examined for its association with bone-density and bone-quality measures. This dual muscle-and-bone interest reflects the same selectivity rationale that motivates the compound generally.

Research has additionally examined functional readouts such as stair-climb performance as composite measures of muscle and skeletal effects. As with the lean-mass data, these results are interpreted as research observations within controlled study designs rather than as demonstrated clinical benefits.

Comparison: MK-2866 vs RAD-140 vs MK-677

MK-2866 is most often compared with RAD-140 (Testolone), a more potent SARM, and with MK-677 (Ibutamoren), which is not a SARM at all but a growth-hormone secretagogue often grouped with these compounds in muscle research. The three act through distinct mechanisms despite overlapping research interest.

The comparison highlights that RAD-140 shares MK-2866's androgen-receptor mechanism at greater reported potency, while MK-677 reaches muscle endpoints through the growth-hormone axis instead. Full entries for each are in the peptide database.

Half-life and pharmacokinetic considerations

MK-2866 is notable for being orally active, a direct consequence of its small non-steroidal structure. It is reported to have a half-life supporting once-daily dosing intervals in research settings — substantially longer than the minutes-to-hours seen with many peptides — which is one reason it is studied as a practical oral research compound rather than an injectable.

Because it engages the androgen receptor centrally, a key pharmacodynamic consideration in the literature is its potential to influence the body's own hormonal feedback over time. Researchers treat the duration and degree of androgen-receptor engagement as primary interpretive variables when reading study outcomes.

Reconstitution and handling considerations

Unlike the lyophilized peptides in this library, MK-2866 is a small molecule that is poorly water-soluble, so it is generally prepared as a solution in a suitable organic co-solvent rather than reconstituted with bacteriostatic water. The goal is a clear, homogeneous solution at a known concentration for reproducible research use.

For peptides that are reconstituted in water, the reconstitution calculator and reconstitution guide describe the general method; MK-2866's handling differs because of its small-molecule chemistry.

• Prepare in a suitable organic co-solvent; not freely water-soluble.
• Confirm a clear, homogeneous solution before use.
• Record the precise working concentration for reproducibility.
• Protect from light and excess warmth.

Storage considerations

As a small molecule, MK-2866 is comparatively stable but is still kept cool, dry, and protected from light for long-term holding. Prepared solutions are refrigerated and protected from light, with concentration and preparation date recorded to support reproducible research.

Research limitations

MK-2866 is an investigational compound that has not been approved as a therapy. Although it is one of the better-studied SARMs, the goal of complete tissue selectivity is a research premise rather than a settled fact, and central androgen-receptor engagement raises endocrine-feedback considerations. It is also a frequent subject of sports anti-doping attention. Reported effects are dose-, duration-, and population-dependent, and it is described here strictly for research reference.

• Complete tissue selectivity is a research premise, not a settled fact.
• Central androgen-receptor engagement affects endocrine feedback.
• Not an approved therapy; data come from specific study populations.
• It is described solely for research reference, not human use.

Frequently Asked Questions

Related Research Profiles

References

1. Dalton JT, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women. J Cachexia Sarcopenia Muscle. 2011.Source
2. Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care. 2009.Source
3. Solomon ZJ, et al. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sex Med Rev. 2019.Source